Please assess the completion status of the following clinical trial:

Trial Title: Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years of age.~* Diagnosed by the Investigator with primary Generalized Anxiety Disorder (GAD) and/or primary Panic Disorder with or without agoraphobia, either primary episode or recurrence, and is positive for GAD or Panic Disorder by the MHS (Mental Health Screener)).~* Receiving a new prescription for all SSRI or SNRI as indicated for GAD or Panic Disorder with or without agoraphobia. Definition of a new prescription in case of a recurrence in symptoms is no prescription or refill of prescription of SSRI or SNRI for the past 6 months.~* Subject is informed and given ample time and opportunity to think about his/her participation and has given his/her written informed consent.~Exclusion Criteria:~* Presence of medical condition or presence of schizophrenia, bipolar disorder, alcohol abuse/dependence or any other primary major psychiatric disorder that, in the opinion of the Investigator, would jeopardize the subject or compromise the subject's ability to participate in the trial.~* Is a current suicide risk in the opinion of the Investigator.~* Has initiated cognitive therapy within two months of Study Day 1.~* Does not speak English or does not hear well enough to be able to perform the Hamilton Anxiety (HAM-A) Rating Scale and Mental Health Screener (MHS) by Interactive Voice Response System (IVRS).~* Has taken a benzodiazepine within the past 30 days.~* History of hypersensitivity or allergic response to any of the components of SSRIs, SNRIs, benzodiazepines, or related drugs.~* If a female of child-bearing potential, is pregnant, nursing, or not using appropriate birth control methods.~* Presence of contraindications to the SSRI or SNRI to be prescribed per the specific package insert.~* Presence of acute narrow angle glaucoma or taking ketoconazole or itraconazole,which are contraindications to Niravam per the package insert.~* History of phenylketonuria (PKU).~* Participation in a previous clinical trial within 30 days prior to Study Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panic: Niravam+SSRI/SNRI (Type: EXPERIMENTAL): Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI
- Panic: SSRI/SNRI alone (Type: EXPERIMENTAL): Panic Disorder: Newly prescribed SSRI or SNRI alone
- GAD: Niravam+SSRI/SNRI (Type: EXPERIMENTAL): Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI
- GAD: SSRI/SNRI alone (Type: EXPERIMENTAL): Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete